Mast Therapeutics Inc (MSTX) declared that the United States Adopted Names (USAN) Council has chosen “vepoloxamer” as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company’s lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. Mast Therapeutics Inc (NYSEMKT:MSTX) shares after opening at $0.73 moved to $0.93 on last trade day and at the end of the day closed at $0.828.Price to cash ratio as 1.73. Mast Therapeutics Inc (NYSEMKT:MSTX) showed a positive weekly performance of 4.81%.
The Bacterin International Holdings Inc (NYSEMKT:BONE) reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01, Stock Ratings Network.com reports. The company had revenue of $8.30 million for the quarter, compared to the consensus estimate of $8.00 million. Bacterin International Holdings Inc (NYSEMKT:BONE) shares advanced 14.29% in last trading session and ended the day on $0.960. BONE return on equity ratio is recorded as -556.70% and its return on assets is -40.50%.Bacterin International Holdings Inc (NYSEMKT:BONE) yearly performance is 9.09%.
In February 2014, the Phase III clinical trial results for Sinovac’s proprietary Enterovirus 71 (“EV71”) vaccine were published online in the February 27th issue of The New England Journal of Medicine (“NEJM”). The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease (“HFMD”), or herpangina, was 94.8% among infants and young children. An anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac’s vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities. Sinovac Biotech Ltd. (NASDAQ:SVA) shares moved up 17.13% in last trading session and was closed at $8.07, while trading in range of $7.16-$8.09.Sinovac Biotech Ltd. (NASDAQ:SVA) year to date performance is 31.86%.
Xencor (NASDAQ:XNCR) issued its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.10, AnalystRatings.Net reports. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.71 million. Xencor Inc (NASDAQ:XNCR) weekly performance is -4.53%. On last trading day company shares ended up $13.06. Xencor Inc (NASDAQ:XNCR) distance from 50-day simple moving average is 25.47%. Analysts mean target price for the company is 14.33$.
Leave a Reply